Ketamine to enhance methadone treatment retention in patients with opioid use disorder and co-morbid depression.
Saved in:
| Title: | Ketamine to enhance methadone treatment retention in patients with opioid use disorder and co-morbid depression. |
|---|---|
| Authors: | Manza P; Kahlert Institute for Addiction Medicine, Department of Psychiatry, University of Maryland Baltimore, Baltimore, MD, USA.; Division of Addiction Research and Treatment, Department of Psychiatry, University of Maryland Baltimore, Baltimore, MD, USA., Belcher AM; Division of Addiction Research and Treatment, Department of Psychiatry, University of Maryland Baltimore, Baltimore, MD, USA., Fitzsimons H; Division of Addiction Research and Treatment, Department of Psychiatry, University of Maryland Baltimore, Baltimore, MD, USA., Spaderna M; Division of Addiction Research and Treatment, Department of Psychiatry, University of Maryland Baltimore, Baltimore, MD, USA., Greenblatt AD; Division of Addiction Research and Treatment, Department of Psychiatry, University of Maryland Baltimore, Baltimore, MD, USA., Smith HC; Division of Addiction Research and Treatment, Department of Psychiatry, University of Maryland Baltimore, Baltimore, MD, USA., Derenoncourt M; Clinical Center, National Institutes of Health, Bethesda, MD, USA., Gann D; Division of Addiction Research and Treatment, Department of Psychiatry, University of Maryland Baltimore, Baltimore, MD, USA., Farooq U; Division of Addiction Research and Treatment, Department of Psychiatry, University of Maryland Baltimore, Baltimore, MD, USA., Kvarta MD; Maryland Psychiatric Research Center, Departments of Psychiatry and Physiology, University of Maryland Baltimore, Baltimore, MD, USA.; Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, Bethesda, MD, USA., DiPaula BA; Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, MD, USA., Merritt S; Lifestream Health Center, Bowie, MD, USA., Mitic I; Baltimore Ketamine Clinic, Sparks, MD, USA., Zarate CA; Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, Bethesda, MD, USA., Gould TD; Departments of Psychiatry, Pharmacology, Anatomy & Neurobiology University of Maryland Baltimore, Baltimore, MD, USA.; Veterans Affairs Maryland Health Care System, Baltimore, MD, USA., Weintraub E; Division of Addiction Research and Treatment, Department of Psychiatry, University of Maryland Baltimore, Baltimore, MD, USA., Kattakuzhy SM; Departments of Psychiatry, Pharmacology, Anatomy & Neurobiology University of Maryland Baltimore, Baltimore, MD, USA.; Veterans Affairs Maryland Health Care System, Baltimore, MD, USA.; Division of Clinical Care and Research, Institute of Human Virology, Division of Infectious Disease, University of Maryland Baltimore, Baltimore, MD, USA. |
| Source: | The American journal of drug and alcohol abuse [Am J Drug Alcohol Abuse] 2025; Vol. 51 (5), pp. 649-657. Date of Electronic Publication: 2025 Aug 22. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 7502510 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-9891 (Electronic) Linking ISSN: 00952990 NLM ISO Abbreviation: Am J Drug Alcohol Abuse Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
